Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. We are a fully integrated, growing, biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates in two key therapeutic areas: neuroscience and oncology. We are an industry leader in sleep disorders and epilepsy and are growing our presence in oncology including hematologic malignancies and solid tumors. Across our commercial franchises and development programs, we focus on innovative therapies and support for adults and children living with these conditions. We actively explore new options for patients including novel compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. Facebook: https://twitter.com/jazzpharma?lang=en https://www.linkedin.com/company/jazz-pharmaceuticals